Flutemetamol

Summary

Flutemetamol (CHEMBL579205) is an approved small molecule; indicated across 2 conditions including alzheimer disease and breast neoplasm.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 2 conditions
• Clinical trials: 9
• Chemistry: 274.32 Da · C14H11FN2OS

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL579205
Name	Flutemetamol
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	10107393
Molecular formula	C14H11FN2OS
Molecular weight	274.32
InChIKey	VVECGOCJFKTUAX-UHFFFAOYSA-N

SMILES: CNC1=C(C=C(C=C1)C2=NC3=C(S2)C=C(C=C3)O)F

IUPAC name: 2-[3-fluoro-4-(methylamino)phenyl]-1,3-benzothiazol-6-ol

Also known as: Flutemetamol, [3h]-flutemetamol, flutemetamol, [3H]-flutemetamol, FLUTEMETAMOL

Parent form; salt/anhydrous children: CHEMBL2042122

Patent coverage: 141 distinct patent families (321 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Amyloid-beta precursor protein.

Bioactivity

ChEMBL activities: 2 potent at pChembl ≥ 5 of 2 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
APP	9.13	Ki	0.74	nM	CHEMBL_ACT_2996748
APP	7.62	IC50	24	nM	CHEMBL_ACT_10948306

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
Alzheimer disease	2	MONDO:0004975	MONDO:0004975
breast neoplasm	2	MONDO:0021100	MONDO:0007254

Clinical trials

Total trials: 9.

Phase distribution

Phase	Trials
PHASE3	5
Not specified	3
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01028053	PHASE3	COMPLETED	Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer’s Disease
NCT01053312	PHASE3	COMPLETED	PET Imaging of Brain Amyloid in Normal Pressure Hydrocephalus
NCT01165554	PHASE3	COMPLETED	Positron Emission Tomography (PET) Imaging of Brain Amyloid Compared to Post-Mortem Levels
NCT01265394	PHASE3	COMPLETED	Positron Emission Tomography (PET) Amyloid Imaging of the Brain in Healthy Young Adult Subjects
NCT02353949	PHASE3	TERMINATED	Investigating the Clinical Consequences of Flutemetamol-PET-scanning
NCT02813070	PHASE2	COMPLETED	Comparison of PET Amyloid Imaging in Japanese and Western Subjects
NCT03174938	Not specified	RECRUITING	The Swedish BioFINDER 2 Study
NCT05457998	Not specified	ENROLLING_BY_INVITATION	BioFINDER-Brown: Examination of Alzheimer’s Disease Biomarkers
NCT06121544	Not specified	RECRUITING	The Swedish BioFINDER - Preclinical AD Study

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).